Molecular NeuroImaging (MNI) is now Invicro. Please click here to visit the Invicro homepage.
Invicro was founded with a mission of improving the role and function of imaging in translational drug discovery and development. To this effort we offer a suite of services and software with applications ranging from tissue to human, from target identification to Phase IV trials across the entire electromagnetic spectrum of imaging techniques.
In 2016, MNI (Molecular NeuroImaging) was acquired by Invicro and now operates as a wholly owned subsidiary of Invicro. Clinical capabilities have been fully integrated into our workflow, and with a team of over 200 employees we provide the most comprehensive set of imaging services across the spectrum of drug development. Read more here.